Vanda Pharmaceuticals announced that NEREUS™ (tradipitant) significantly reduces vomiting caused by GLP-1 receptor agonist therapy, including semaglutide. In a Phase III trial, NEREUS™ lowered any vomiting by 27%, frequent multi-day vomiting by 60%, and extreme vomiting by 81% compared to placebo. This improvement could help more patients tolerate and continue GLP-1 treatments, which often cause nausea and vomiting leading to discontinuation. Vanda plans to seek FDA approval to expand NEREUS™ use for this indication.
Vanda Pharmaceuticals' study results on NEREUS™ for preventing GLP-1-induced vomiting provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 27, 2026 17:02 WIB: out of 150 priced US health-sector stocks, 60 rose and 78 fell. Notable movers include MRVI at USD 7.22 with a -4.75% change, CNC at USD 65.00 down 4.51%, and BNGO at USD 1.12 down 3.45% with 100% sell order activity. The most notable figure is BNGO's full sell-side order activity.
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...
